A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer

Inclusion Criteria: * Subjects who understand and sign the consent form for this study * Males age ≥18 years * Subjects diagnosed with metastatic hormone-sensitive prostate cancers (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Expected survival time of at least 24 months * Adequate hematologic, renal, and liver function: WBC greater than 3.5 x 109/L; Absolute neutrophils count greater than 1.5 x 109/L; Platelet count greater than 80 x 109/L; Hemoglobin at least 90g/L; AST less than 2 x upper limit of normal (ULN); Creatinine less than 1.5 x ULN * No obvious abnormalities in the electrocardiogram Exclusion Criteria: * Clinically significant cardiovascular disease: New York Heart Association (NYHA) class III or IV chronic congestive heart failure, coronary heart disease (myocardial infarction within 6 months); cardiac arrhythmia requiring anti-arrhythmic drug (beta-blocker or digoxin is allowed to be used); uncontrolled high blood pressure * HIV infection * Acute exacerbation of chronic hepatitis A or hepatitis B infection * The subject has uncontrollable seizures required pharmacotherapy (such as steroids or antiepileptic drugs) * The subject has a history of allogeneic organ transplants * Subject with irregular hemorrhagic disease * The subject receives dialysis treatment The subject has a history of other malignant tumor except subjects with curable basal cell carcinoma, superficial bladder tumor or other tumors has been cured over three years of study entry * The subject has a history of gastrointestinal hemorrhage within 30 days of study entry * The subject has an allergic history or is allergic to the drug in this study * The subject has serious diseases of respiratory, nervous or mental system * Subject with immune disease, auto-immune disease requires systemic ongoing immunosuppressive therapy * The subject has problems with drug or alcohol abuse * Major surgery within 4 weeks of enrollment * Prior autologous bone marrow transplantation within 4 weeks of enrollment * The subject has participated in any other therapeutic clinical trial with an experimental drug in the 4 weeks prior to this trial * The subject has any other unsuitable or adverse condition to be determined by the investigator * Any medical intervention or any circumstances that could compromise the safety and compliance of the trial subjects